Back to discover
Drug

Latanoprost

Approved · EMA
Emerging researchLate-stage developmentRising momentum
Also known as Iyuzeh, Latanoprost Ophthalmic, Rocklatan, Xalatan+4 more

Iyuzeh, Latanoprost Ophthalmic, Rocklatan, Xalatan, Xelpros, 5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)-1-METHYLETHYL ESTER, (1R-(1.ALPHA.(Z),2.BETA.(R*),3.ALPHA.,5.ALPHA.))-, Latanoprostum, isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate.

RxNorm43611ChEMBLCHEMBL1051UNII6Z5B6HVF6O
3
Research papers
5
Active clinical trials
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Masked, Randomized, Prospective Study of QLS-111-FDC in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Clinical trial2026-07-24Primary completion · ClinicalTrials.gov

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Using Erythrocyte Mediated Angiography In Vivo

Clinical trial2026-07-02Results expected Q1 2027 · ClinicalTrials.gov

A Phase III Study Including a Single-Arm, Open-Label, Multi-Dose PK Study Cohort and a Randomized, Evaluator-Masked, Active Drug Controlled, Parallel Group, Multicenter, Bridging Study Cohort With a Long-term Follow-up Phase Assessing the Efficacy and Safety of DE-117B Eye Drops in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Clinical trial2026-05-15Results expected Q3 2026 · ClinicalTrials.gov

Optic Nerve Head Strain in Non-glaucoma Subjects

Clinical trial2026-04-08Results expected Q1 2028 · ClinicalTrials.gov

Stop Retinal Ganglion Cell Dysfunction Study

Clinical trial2024-10-04Terminated · ClinicalTrials.gov

Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% Versus Brimionidin Tartrate 0.2% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study

Clinical trial2024-10-01Completed · ClinicalTrials.gov

Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study

Clinical trial2024-08-30Completed · ClinicalTrials.gov

Approval: Catiolanze (EMA)

Regulatory2023-11-15EMA

The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface.

Research2018-11-01Eye & contact lens

Drug Safety Update: Latanoprost (Xalatan): increased reporting of eye irritation since reformulation

Regulatory2015-07-20MHRA

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.

Research2014-12-08The British journal of ophthalmology

Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy.

Research2012-06-01Archives of ophthalmology (Chicago, Ill. : 1960)

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Latanoprost
Aliases & brands
IyuzehLatanoprost OphthalmicRocklatanXalatanXelpros5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)-1-METHYLETHYL ESTER, (1R-(1.ALPHA.(Z),2.BETA.(R*),3.ALPHA.,5.ALPHA.))-Latanoprostumisopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
RxNorm CUI
43611
ChEMBL ID
CHEMBL1051
UNII
6Z5B6HVF6O
Regulatory jurisdictions
mhraema

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2023-11-15
Latest approval
2023-11-15
Authorities
EMA · MHRA
Total events
2
emaEuropean Medicines Agency· 1 event
2023-11-15Approval
Approval: Catiolanze (EMA)
Indication: Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension. Catiolanze is indicated for the… Show full indication

Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension. Catiolanze is indicated for the reduction of elevated IOP in children from 4 years of age and adolescents with elevated IOP and paediatric glaucoma.  

Evidence ↗
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2015-07-20Safety communicationSafety
Drug Safety Update: Latanoprost (Xalatan): increased reporting of eye irritation since reformulation
Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

79 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
79
registered trials across all phases
LATEST COMPLETION 2024
5
Active studies
3
Recruiting
49
Late-stage (III+)
51
Completed
23
Discontinued
PHASE DISTRIBUTIONn = 79
Early Phase 12Phase 16Phase 1 / 23Phase 219Phase 2 / 32Phase 316Phase 421Phase N / A10

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Using Erythrocyte Mediated Angiography In Vivo

RecruitingPH IVUniversity of Maryland, Baltimoren=502027

Department of Ophthalmology, Rigshospitalet-Glostrup Valdemar Hansens Vej 13, 2600 Glostrup, Denmark

RecruitingPH IVRigshospitalet, Denmarkn=282026

African Glaucoma Laser Trial

WithdrawnPH IVWest Virginia University2024

Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation

Unknown statusPH IVShaimaa Fawzy Abdel-rady Abdel-latifn=1502024

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients

CompletedPH IVCHA Universityn=572020

Recent completions

Trials that read out recently, adding to the completed evidence base.

Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% Versus Brimionidin Tartrate 0.2% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study

CompletedPH IZagazig Universityn=562024

Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study

CompletedPH IZagazig Universityn=462024

Phase 2 Multi-Center, Double-Masked, Randomized, 28-Day Study to Assess the Efficacy, Safety and Tolerability of Single or Twice Daily Doses of AKB-9778 Ophthalmic Solution as an Adjunct to Latanoprost in Patients With Ocular Hypertension (OHT) or Open Angle Glaucoma (OAG)

CompletedPH IIEyePoint Pharmaceuticals, Inc.n=1942020

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients

CompletedPH IVCHA Universityn=572020

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders

CompletedN/ASanten Pharmaceutical (Taiwan) Co., LTDn=12019

A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Compared With Latanoprost Ophthalmic Solution 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension- PEONY Study

CompletedPH IIISanten Pharmaceutical Co., Ltd.n=3702019

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20122018
Journals, researchers & institutions
Top journals
  • Archives of ophthalmology (Chicago, Ill. : 1960)1
  • Eye & contact lens1
  • The British journal of ophthalmology1
Leading researchers
  • Fan S1
  • Gangahar C1
  • Gulati V1
  • Hark LA1
  • Ichhpujani P1
  • Katz LJ1
  • Kaufman PL1
  • Maslonka MA1
Leading institutions
free-text, unnormalised
  • Glaucoma Research Center (K.R.1
  • Hamilton Glaucoma Center and Department of Ophthalmology1
  • Stanford University School of Medicine1
  • University of Nebraska Medical Center1
  • University of Wisconsin1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.